Breast Cancer Drug Financial Assistance Programme – Halaven® (Application for the programme has ended on 9 Apr 2020)


Sponsored By Self Photos / Files - 71_2



Prescription drugs can become a big financial burden for breast cancer patients. In this connection, the Breast Cancer Drug Financial Assistance Programme, a joint effort between Hong Kong Breast Cancer Foundation (HKBCF) and pharmaceutical companies, is dedicated to helping breast cancer patients who are financially challenged by their medication costs.

1. About the Breast Cancer Drug Financial Assistance Programme–HalavenR

Sponsorship Arrangement

  • This programme is tailored for patients within the public health system and under the care of the Hospital Authority
  • Maximum subsidy per patient: up to HK$101,320 per year
  • Quota: 10 patients (HKBCF ceases to receive applications on 9 April 2020.)
  • On first-come-first-serve base

Subject to the applicant’s financial status, HK$1,490 will be reimbursed for each vial of HalavenR. Subsidy period of each applicant is 12 months. The maximum subsidy of HK$ 101,320 per year is calculated with reference to the number of vials of HalavenR consumed with proof of original official medication receipts submitted by the applicant, or as stated in the Doctor’s Referral Letter, whichever is lower.

Applicant should submit the application early. Only official medication receipts issued within 4 months of the application date are accepted.

A qualified applicant would be entitled for one-year financial subsidy on prescribed HalavenR and applicant is required to submit the application every 12 months for the renewal of the drug financial assistance.

Applicants with medication insurance cover(s) should claim for their insurance under the cover(s) before making applications under this Programme.


2. Who is eligible for the Breast Cancer Drug Financial Assistance Programme–HalavenR?


Qualified applicants must fulfill ALL the criteria below:

Clinical Requirement:

  • This programme is only for the patients who are indicated for HalavenR treatment in accordance with the approved indication by Hong Kong Department of Health; and HalavenR must be prescribed by:

1. Registered doctors in Department of Surgery, Department of Medicines, Department of Clinical Oncology or Oncology Center of public hospitals in Hong Kong; or

2. Registered doctors in Department of Surgery, Department of Medicine or Department of Clinical Oncology of local universities in Hong Kong

Residence Requirement

A permanent resident of HKSAR

Financial Requirement

The average monthly individual income must not exceed HK$50,000.


Financial criteria
Average monthly individual income in the last 12 
months (HK$)
Financial Assistance Amount (HK$) Maximum Yearly Subsidy Amount (HK$)
≦$50,000 $1,490/vial $101,320


1. Applicants who has benefited from other drug financial assistance programmes can also applied for this drug financial assistance programme.


3. Documents required for first time application

Original copy of:

  1.  Breast Cancer Drug Assistance Program -HalavenR Application Form
  2.  Doctor's referral letter for Breast Cancer Drug Assistance Program -HalavenR
  3. Medication receipts

Photocopy of:

  1. HKSAR identity card
  2. Related financial proof - Financial qualification is evaluated based on individual financial situation. Applicant must provide supporting documents such as proof of income


Documents for financial assessment

Proof of individual income

Employed persons
  • bank statement, bank account passbook, salary statement or certified documents issued by the employer
Self-employed persons
  • Latest tax return statement or income declaration
Unemployed persons
  • Documentary proof of unemployment (e.g. letter of termination from the employer, etc.)
Beneficiary of other drug financial assistance programme(s)
  • Proof of successful application of such programme(s)


4. Application procedure

Please fill in the  application form / reimbursement claim form which can be downloaded from or obtain in person at HKBCF office. Completed form should be returned by post with required documents to:

Hong Kong Breast Cancer Foundation

22/F, Jupiter Tower, 9 Jupiter Street, North Point, Hong Kong.

(Please mark "Application for Breast Cancer Drug Financial Assistance Programme -HalavenR" on the envelope.)


Qualified applicant will be notified individually by post upon HKBCF's validation of submitted application and relevant supporting documents. Generally speaking, it will take approximately 1 week for the HKBCF to process each application. Confirmation of the successful application will be issued thereafter. Reimbursement will be arranged by cheque made payable to the applicant by post.


5. Important notice


  • Please read carefully the eligibility criteria to find out whether you are qualified to join the Programme.
  • Once the applicant is qualified, only the successful application confirmation and official medication receipts are required for subsequent reimbursements.


  • Please state clearly on the doctor's referral letter the dosage of the drug and number of vial your patient is prescribed.


  • This Programme is for individual patients only and is not intended for hospitals.
  • HKBCF does not endorse or promote any drugs under the Breast Cancer Drug Financial Assistance Programme. Applicants should consult their doctors for questions on the drugs.
  • HKBCF may request further information and supporting documents from applicant, interview applicant and household members, make home visits, contact applicant's doctor-in-charge, medical insurance or other similar drug financial reimbursement agents for more information.
  • All personal information collected will be treated in strictest confidence and in accordance to the Personal Data (Privacy) Ordinance.
  • The HKBCF reserves the right to make the final decision and decline any application without providing reason.



Eisai is a multinational pharmaceutical company headquartered in Tokyo, Japan with strong R&D capabilities. As a human health care (hhc) company, Eisai seeks innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide. As part of its hhc mission, Eisai continues to grow its commitment to oncology through research and clinical development, and through HOPE TO HER patient assistance programme to strengthen its commitment to breast cancer patients.

What is HalavenR

  • The active ingredient of HalavenR is eribulin. It is a microtubule dynamics inhibitor and a synthetic analogue of halichondrin B derived from the marine sponge Halichondria okadai. It exerts its effects by disrupting cell division, resulting in cell death.1

    HalavenR is a new class of chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer (who have previously received at least one chemotherapeutic regimens for advanced disease including an anthracycline and a taxane).1 Consult your physician for details about the drug.

How is HalavenR applied?

  • HalavenR will be injected directly into the vein only under the supervision of a qualified physician. HalavenR will be given in “cycles”, with each cycle lasting 21 days. On days 1 and 8 of every cycle, patient will receive an injection over 2 to 5 minutes. The amount of HalavenR patient received will depend on her body surface area (m2) calculated from weight and height. 1

Efficacy of HalavenR

  • In a large-scale clinical trial, women with pretreated locally recurrent or metastatic breast cancer were recruited to receive either HalavenR or treatment of their physician’s choice (e.g. chemotherapy or hormonal therapy) as the control. It showed a significant improvement in median overall survival time of patients receiving HalavenR treatment, compared to the control.2

Safety and tolerability of HalavenR

  • HalavenR is well tolerated; common side effects include neutropenia, peripheral neuropathy, fatigue, nausea and alopecia,etc.1



  1. 1. HalavenR package insert.
  2. 2. Cortes J, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011; 377; 914–923.

 The above company and product information is provided by Eisai (HK) Co., Ltd.